Trial
NCT05286827
Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Pancreatic Acinar Cell Carcinoma
Intervention
Olaparib
Why stopped
The study was terminated due to low accrual and insufficient efficacy seen in first few participants treated.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-11